Research
Hormonal
Surgical weight loss induces specific psychobiological changes, including altered eating patterns (decreased bingeing, increased satiety) and hormonal shifts (elevated enteroglucagon, decreased pancreatic polypeptide), which help regulate the body weight set point.
Surgery not only restricts food intake but also changes the body's hormonal signals for hunger and satiety, which may help maintain weight loss by altering the body's 'set point'.
ModerateSupportsMEDIUM confidence
These findings suggest a profound change in the biology of these persons... following intestinal bypass surgery... levels of enteroglucagon were elevated... pancreatic polypeptide... decreased.
Why this rating
Based on specific biochemical studies cited.
Source
Psychological and social aspects of the surgical treatment of obesity
Albert J. Stunkard et al. · American Journal of Psychiatry · 1986
DOI 10.1176/ajp.143.4.417
narrative_reviewCited 186×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Surgical treatment (intestinal bypass or gastric restriction) produces significant, sustained weight loss and remission of obesity-related comorbidities (hypertension, diabetes, pulmonary issues) in severely obese patients, whereas conservative treatments are largely ineffective.Good
- Surgical weight loss leads to significant psychosocial improvements, including enhanced body image, self-esteem, marital satisfaction, and vocational functioning, often reversing pre-existing psychological disturbances.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →